RxDoctor Payments Data

John Gnann, MD

Infectious Disease · Charleston, SCNPI 1467498659

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $33,901 of the $39,149 with a category attached, or 86.6%. 5 manufacturers reported payments, led by GSK at 48.5% of the total. Among infectious disease clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$39,149in general payments, 2019–2025

Across 40 payments — averaging $978.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$19K
  • Biocryst Pharmaceuticals, Inc.$15K
  • Merck Kgaa$3K
  • Modernatx, Inc.$2K
  • Perrigo Company PLC$450
$1,000in research payments, 2019–2025

Across 1 payment — averaging $1000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Gilead$1K

What the payments were for

  • Consulting fees$33,90187%
  • Speaking & faculty fees$2,7207%
  • Travel & lodging$1,9135%
  • Food & beverage$6152%

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK33$19,004
Biocryst Pharmaceuticals, Inc.4$14,550
Merck Kgaa1$2,720
Modernatx, Inc.1$2,425
Perrigo Company PLC1$450

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$39,149 in reported general payments places this provider in the 95th percentile of 102 infectious disease providers in South Carolina.

See all infectious disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$5,038
Medicare patients
39
Services billed
44

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other infectious disease in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →